Pre-operative endocrine therapy: focus on the clinical and biological results of the IMPACT trial

Abstract

randomised to the anastrozole alone group; 108 to the tamoxifen alone; and 109 to the combination group. All had confirmed oestrogen receptor (ER) positive, invasive breast carcinoma and the median age was 73 years. Post-menopausal patients with small breast carcinomas, not necessar-ily requiring mastectomy, were also eligible for trial entry and the median tumour size was 4 cm for each treatment group.